BioSpace News Archive

Camena Bioscience, a synthetic biology company providing genes to the pharmaceutical and biotechnology industries, announced it has appointed Dr Nicola Thompson as Chair of its Board of Directors.

Kaneka Corporation has acquired all shares of Japan Medical Device Technology Co., Ltd., a developer and manufacturer of medical devices, on November 30, 2023, and made it a wholly owned subsidiary.

West Pharmaceutical Services, Inc. announced that the Company’s Board of Directors has approved a first-quarter 2024 dividend of $0.20 per share.

Zomedica Corp. today announced the presentation of new clinical data supporting new indications for shock wave therapy at the recent meeting of the American Association of Equine Practitioners (AAEP) annual meeting in San Diego, California.

Pharvaris (Nasdaq: PHVS) today announced positive top-line data from the CHAPTER-1 Phase 2 clinical study meeting its primary endpoint, with deucrictibant demonstrating statistically significant and clinically meaningful results of deucrictibant as an oral preventative treatment for people living with HAE.

Microbix Biosystems Inc. announces the initiation of a Normal Course Issuer Bid program for the repurchase and cancellation of outstanding common shares.

Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to breaking through barriers in gene therapy and neurology, today announced that it has selected a lead development candidate for its superoxide dismutase 1 (SOD1)-mutated amyotrophic lateral sclerosis (ALS) gene therapy program.

Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that the U.S. Food and Drug Administration (FDA) has extended by three months the review period of its supplemental new drug application (sNDA) requesting approval of XHANCE as a treatment for chronic rhinosinusitis.

Kamada Ltd. announced the execution of a binding memorandum of understanding with Kedrion for the amendment and extension of the KEDRAB® U.S. distribution agreement between the parties.

ImmunoPrecise Antibodies Ltd. announced that it has priced its underwritten public offering of 1,100,000 common shares at a public offering price of $1.00 per share.